COSCIENS Bizerma停止投资马西莫林; CMO将离职

2024-12-23 21:49

COSCIENS Biopharma (NASDAQ:CSCI), on Monday, provided a corporate update and reiterated its pipeline prioritization. The company said it has streamlined efficiencies and taken cost-cutting measures to refine operations and development pathway forward.
Avenanthramides Tablets in Development as an Anti-Inflammatory: The Phase 1-2a clinical trial has fully completed the Phase 1 part of the study with 72 subjects tested. No significant side effects have been observed. The company expects the Phase 2a efficacy study will be initiated in Q1 2025, with expected completion in Q3 2025.
The company announced in August that the Phase 3 safety and efficacy study AEZS-130-P02 evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency had failed to meet its primary endpoints according to the definitions in the study protocol.
Based on the results of the study, the company is prioritizing its pipeline moving forward and repositioning the company as a pure play Life Science’s business offering natural-based products.Therefore, the company has decided to not make any future investments in macimorelin for the diagnosis of CGHD.
Consequently, in order to further ensure the streamlining of operations and reduce costs, the roles of some additional members of management have been terminated, including Dr. Nicola Ammer, Chief Medical Officer, which will be ending on March 31, 2025.
COSCIENS Biopharma (CSCI) shares were down 1.97% in premarket trading.

More on COSCIENS Biopharma